Personalis, Inc. (PSNL) Stock Price & Analysis

Personalis, Inc. (PSNL) closed at USD 15.85 on Friday, October 23, 2026, up 0.19% on the day. The US market is currently closed; this is not a live price.

The prior close was USD 15.85; the Oct 23, 2026 session ranged USD 15.67–15.89 on volume of 1,115,858 shares. Market capitalization is —, with a 52-week range of USD 4.96–18.89 (NGM). Source: Nexqual, retrieved October 24, 2026 at 14:22 UTC.

Also available as compact Markdown for AI agents: nexqual.com/PSNL.md

Key facts (PSNL)

• Last four reported quarters (through Jun 30, 2026): revenue $69.7M, net income -$107M (-153.8% margin), free cash flow -$101M (SEC filings).
• Insider open-market sales, last ~7 months: 12 Form 4 filings, $7.4M; 4 not under a Rule 10b5-1 plan ($267K); 0 by opportunistic insiders, 12 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Hold (mean 2.80 on a 1–5 scale) (5 analysts), mean target USD 15.17 (range 13–16.25).
• Total return with dividends: 1Y +63.7% vs S&P 500 +13.4%; 5Y -19.2% vs S&P 500 +76.9%.
• Next earnings: 2026-11-03, EPS estimate USD -0.25, revenue estimate $21.3M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (PSNL)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (PSNL)

Insider sales (SEC Form 4, open-market, last ~7 months) (PSNL)

8 of 12 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (PSNL)

Consensus Hold (mean 2.80 on a 1–5 scale), 5 analysts; mean target USD 15.17 (low 13, high 16.25).

Rating changes, last 120 days:

Total return (dividends reinvested) (PSNL)

PSNL suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 26, 2026.

Companies that name PSNL in their SEC reports

PSNL customer concentration

In the period ended Jun 30, 2026, 3 direct customers each accounted for at least 10% (37%, 13%, 12%) of revenue, per the company's 10-Q filed Aug 4, 2026. The company does not name them.

PSNL company outlook (results filed Aug 4, 2026)

• “As a result of the announcement on July 20, 2026 that Personalis and Tempus AI, Inc. have entered into an Agreement and Plan of Merger, Personalis will no longer provide financial guidance or conduct a quarterly earnings conference call.”

Quoted word-for-word from the SEC 8-K results press release.

PSNL analyst estimates and revisions

PSNL options: expected move

Options price a move of about ±11.7% (±$1.85) by Nov 20, 2026, which includes earnings on Nov 3, 2026. Over the last 8 reports the stock moved ±11% on average.

30-day implied volatility 30.2% vs 13.9% realized over the last 30 trading days. Put/call ratio (volume) 0.03. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 24, 2026 at 14:22 UTC)

Technical Analysis (PSNL)

Nexqual's technical model rates PSNL "SELL" based on 1 bullish and 4 bearish signals across 127 daily candles, as of October 24, 2026 at 14:22 UTC.

Analyst Ratings (PSNL)

Wall Street analysts rate PSNL "Hold" based on 5 analysts, with a mean price target of USD 15.17 (range USD 13–16.25), per Nexqual as of October 24, 2026 at 14:22 UTC.

Earnings (PSNL)

Recent Earnings History

Source: Nexqual, October 24, 2026 at 14:22 UTC.

Financials & Fundamentals (PSNL)

Source: Nexqual, October 24, 2026 at 14:22 UTC.

Ownership (PSNL)

Source: Nexqual, October 24, 2026 at 14:22 UTC.

From Personalis, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• The principal markets for our testing services are the United States, Europe (including the U.K.), and rest of the world, including Asia-Pacific, which accounted for 90%, 9%, and 1%, respectively, of our revenue for the year ended December 31, 2025.
• Anderson Cancer Center; University Medical Center Hamburg-Eppendorf (also known as UKE); Criterium and the Academic Breast Cancer Consortium; Yale Cancer Center; Aarhus University; British Columbia Cancer; and University Health Network, that will focus on building the evidence-base for our technology and these indications.
• Specifically, our success is dependent on our ability to obtain and maintain proprietary protection for our unique technology, processes, and approaches, defend and enforce our intellectual property rights, and operate our business without infringing, misappropriating, or otherwise violating valid and enforceable intellectual property rights of others.
• Because of the ultra-high sensitivity of our technology, we are initially focusing on three indications: breast cancer, lung cancer, and immunotherapy (IO) monitoring, where early-stage cancer recurrence historically has been difficult to detect.

Partnerships

• In November 2023, we entered into an agreement with Tempus to co-commercialize NeXT Personal Dx in the clinical diagnostics market.
• In July 2025, we further expanded our collaboration partnership with Tempus to authorize Tempus to market NeXT Personal Dx for colorectal cancer and extend the term of the Tempus Agreement through November 25, 2029.

Legal & Regulatory Risks (Item 1A, quoted)

• Our tests may be subject to regulatory action if regulatory agencies or authorities determine that our tests do not appropriately comply with statutory and regulatory requirements enforced by the FDA, or equivalent foreign regulatory authorities and/or CLIA requirements for quality laboratory testing or equivalent foreign requirements.
• The process for submitting a 510(k) premarket notification and receiving FDA clearance usually takes from three to 12 months, but it can take significantly longer and clearance is never guaranteed.
• Failure to comply with federal, state, and foreign laboratory licensing requirements and the applicable requirements of the FDA or any other regulatory authority, or equivalent foreign regulatory authority, could cause us to lose the ability to perform our tests, experience disruptions to our business, or become subject to administrative or judicial sanctions.
• We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents. Additionally, certain data privacy and security obligations may require us to implement and maintain certain measures to protect our information technology systems and sensitive information.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 14:22 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt